High-dose Polyestradiol Phosphate versus Total Androgen Blockade

Donec sed odio dui. Donec ullamcorper nulla non metus auctor fringilla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit tempus porttitor. Aenean eu leo quam. Pellentesque ornare sem lacinia quam venenatis vestibulum.


5 publications

Publications of the SPCG-5 trial

Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival

Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ

Clin Cancer Res. 2007

Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the scandinavian prostate cancer group study 5

Jønler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, Waldén M, & the Scandinavian Prostate Cancer Group Study 5 Study Group

Scand J Urol Nephrol. 2005

Parenteral Estrogen versus Combined Androgen Deprivation in the Treatment of Metastatic Prostatic Cancer. Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E and the SPCG-5 Study Group

Scand J Urol Nephrol. 2002

Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate

Spetz A-C, Hammar M, Lindberg B, Spångberg A, Varenhorst E and the Scandinavian Prostatic Cancer Group-5 Trial Study

J Urol. 2001